ClinicalTrials.gg
RecruitingNCT07132112Updated Apr 16, 2026

GT719 Injection for Moderate to Severe Refractory Autoimmune Disease

An Early Phase 1 interventional study of GT719 Injection in Auto Immune Disease, sponsored by Grit Biotechnology. Recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-04-16.

Sponsored by Grit Biotechnology · Early Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This study is a prospective single-arm open-label clinical trial, including dose escalation and expansion phase, aims to evaluate the safety, efficacy, and cellular pharmacokinetics of GT719 Injection in patients with moderate to severe refractory autoimmune disease. A total of 30 subjects will be enrolled in this study.

02

Conditions studied

  • Auto Immune Disease
03

In context

Lead sponsor

Grit Biotechnology is the lead sponsor of 30 studies on the registry; 17 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1. Voluntarily enrolled in the study, signed an form, willing and able to comply with the study protocol.
  • 2. Aged 18 to 65 years (inclusive), regardless of gender.

Specific inclusion criteria:

  • 3. Participants with systemic lupus erythematosus (SLE)

    1. Meets the classification criteria for SLE in the 2019 European League Against Rheumatism/American College of Rheumatology (EULAR/ACR);
    2. Disease activity score SLEDAI-2000 ≥ 6, with at least one British Islet Lupus Assessment Group Index (BILAG-2004) Grade A (severe manifestations) or two Grade B (moderate manifestations) organ scores, or both; Or the disease activity score SLEDAI-2000 ≥ 8;
  • 4. Participants with idiopathic inflammatory myopathy (IIM)

    1. Complies with the 2017 EULAR/ACR classification criteria for inflammatory myopathy (including DM, PM, ASS, and NM)
    2. Myositis antibody positive;
    3. . Meets the definition of recurrence, or progressive;
  • 5. Participants with systemic sclerosis

    1. . Meet the 2013 American College of Rheumatology (ACR) SSc criteria;
    2. . SSc related antibodies are positive;
    3. . Meets the definition of refractory or progressive recurrence

Exclusion criteria

Exclusion Criteria:

  • 1. Within 3 weeks prior to lymphodepleting chemotherapy, complement inhibition therapy (such as Ecuzumab) has been used;
  • 2. Received attenuated within 4 weeks before lymphodepleting chemotherapy;
  • 3. Having undergone major surgery within the 8 weeks prior to screening, or planning to undergo surgery during the study period;
  • 4. Medical history of organ transplantation;
  • 5. Previously received CAR-T product therapy targeting any target (excluding GT719 therapy);
  • 6. According to the investigator's judgment, the situations that hinder participants from participating in the entire trial, confound the trial results, or participate in the trial that are not in the best interests of the participants.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    GT719 Injection treatment group

    GT719 Injection

    Biological: GT719 Injection

Interventions

06

What researchers measure

Primary outcomes

  1. Proportion of participants experiencing dose limiting toxicity

    Proportion of participants experiencing dose limiting toxicity (DLT) within 28 days after cell infusion

    Time frame: 28 days

  2. Incidence of treatment-emergent adverse events

    Safety assessments are conducted using the NCI-CTCAE version 5.0 standards

    Time frame: 2 years

Secondary outcomes

  1. Efficacy outcomes for SLE

    SLE response index 4 (SR-4) response

    Time frame: 14 days; 1, 2, 3 and 6 Months post GT719 infusion

  2. Efficacy outcomes for Systemic Sclerosis

    ACR-CRISS score (CRISS score≥0.6 improvment, \<0.6 no improvment)

    Time frame: 14 days; 1, 2, 3, and 6 months post GT719 infusion

  3. Efficacy outcomes for Inflammatory Myopathy

    Total Improvement Score (TIS)

    Time frame: 14 days; 1, 2, 3, and 6 months post GT719 infusion

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2025 (actual). Primary completion is estimated for Aug 2028, 34 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 14, 2025
First posted
Aug 20, 2025
StartActual
Oct 28, 2025
Primary completionEst.
Aug 2028
CompletionEst.
Aug 2028
Last update
Apr 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07132112
Lead sponsor
Grit Biotechnology
Collaborators
Affiliated Hospital of Nantong University
Responsible party
Sponsor
First posted
Aug 20, 2025
Start date
Oct 28, 2025
Primary completion
Aug 2028 (estimated)
Completion
Aug 2028 (estimated)
Last update
Apr 16, 2026

Study contacts

Zhifeng Gu
Contact
guzhifeng@126.com
086-13706291941

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: GT719

Start the discussion